Market Spotlight: Systemic Hypertension
Market Spotlight: Systemic Hypertension
$1,318.00
This Market Spotlight report covers the Systemic Hypertension market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
- Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
- The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, and topical formulations.
- The only high-impact upcoming event in the systemic hypertension space is topline Phase III trial results for firibastat. The overall likelihood of approval of a Phase I systemic hypertension asset is 5.4%, and the average probability a drug advances from Phase III is 65.2%. Drugs, on average, take 6.5 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.
- There have been 44 licensing and asset acquisition deals involving hypertension drugs during 2014–19. The largest deal was the $1,050m exclusive licensing and collaboration agreement between Esperion and Daiichi Sankyo Europe in 2019 for the development and commercialization of bempedoic acid and the bempedoic acid/ezetimibe combination tablet in the European Economic Area and Switzerland.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for hypertension have been in the late phases of development, with 53% of trials in Phase III–IV, and 47% in Phase I–II.
- The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major EU markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 385 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Pharmacological therapy
10 EPIDEMIOLOGY
14 MARKETED DRUGS
33 PIPELINE DRUGS
39 RECENT EVENTS AND ANALYST OPINION
39 Multiple Drugs for Systemic Hypertension (June 25, 2019)
39 Symplicity Renal Denervation System for Systemic Hypertension (May 22, 2019)
40 CIN-107 for Systemic Hypertension (May 14, 2019)
41 Livongo Connected Meter for Systemic Hypertension (March 18, 2019)
42 Peregrine System Infusion Catheter for Systemic Hypertension (March 7, 2019)
44 Firibastat for Systemic Hypertension (November 11, 2018)
46 BackBeat Cardiac Neuromodulation Therapy for Systemic Hypertension (September 24, 2018)
48 Paradise System for Systemic Hypertension (July 10, 2018)
52 KEY UPCOMING EVENTS
53 PROBABILITY OF SUCCESS
54 LICENSING AND ASSET ACQUISITION DEALS
54 Daiichi Sankyo Pays ¥9.5bn For Three Marketed Astellas Products
54 Hikma Strikes Deal To Supply 14 To Civica Rx
55 CinCor Licenses Roche Hypertension Candidate, Raises $50m
56 PARENT PATENTS
57 REVENUE OPPORTUNITY
61 CLINICAL TRIAL LANDSCAPE
62 Sponsors by status
63 Sponsors by phase
64 Recent events
65 BIBLIOGRAPHY
65 Prescription information
69 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of systemic hypertension, 2017–26
33 Figure 2: Overview of pipeline drugs for systemic hypertension in the US
34 Figure 3: Pipeline drugs for systemic hypertension, by company
34 Figure 4: Pipeline drugs for systemic hypertension, by drug type
34 Figure 5: Pipeline drugs for systemic hypertension, by classification
46 Figure 6: Firibastat for Systemic Hypertension (November 11, 2018): Phase IIb – NEW-HOPE
48 Figure 7: BackBeat Cardiac Neuromodulation Therapy for Systemic Hypertension (September 24, 2018): First-In-Man Study (EU & Chile)
52 Figure 8: Key upcoming events in systemic hypertension
53 Figure 9: Probability of success in the systemic hypertension pipeline
54 Figure 10: Licensing and asset acquisition deals in systemic hypertension, 2014–19
56 Figure 11: Parent patents in systemic hypertension, 2019–24
56 Figure 12: Parent patents in systemic hypertension, 2025–37
61 Figure 13: Clinical trials in hypertension
61 Figure 14: Top 10 drugs for clinical trials in hypertension
62 Figure 15: Top 10 companies for clinical trials in hypertension
62 Figure 16: Trial locations in hypertension
63 Figure 17: Hypertension trials status
64 Figure 18: Hypertension trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of systemic hypertension (000s), 2017–26
13 Table 2: Prevalent cases of systemic hypertension (000s), by gender, 2017
15 Table 3: Marketed drugs for systemic hypertension
36 Table 4: Pipeline drugs for systemic hypertension in the US
39 Table 5: Multiple Drugs for Systemic Hypertension (June 25, 2019)
40 Table 6: Symplicity Renal Denervation System for Systemic Hypertension (May 22, 2019)
41 Table 7: CIN-107 for Systemic Hypertension (May 14, 2019)
42 Table 8: Livongo Connected Meter for Systemic Hypertension (March 18, 2019)
43 Table 9: Peregrine System Infusion Catheter for Systemic Hypertension (March 7, 2019)
44 Table 10: Firibastat for Systemic Hypertension (November 11, 2018)
47 Table 11: BackBeat Cardiac Neuromodulation Therapy for Systemic Hypertension (September 24, 2018)
49 Table 12: Paradise System for Systemic Hypertension (July 10, 2018)
58 Table 13: Historical global sales, by drug ($m), 2014–18
60 Table 14: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the